Hemab Therapeutics Holdings, Inc.
corporate_fare Company Profile
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for COAG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-17, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 8 rated 8 or above. Recent SEC coverage for COAG spans 10-Q, 8-K, SCHEDULE 13D, 4.
Recent high-impact activity:
- Hemab Doses First Patient in Phase 1 Trial of HMB-003 for Heavy Menstrual Bleeding
- Hemab Posts Q2 Loss, Extends Cash Runway to 2029, but Flags Unremediated Material Weaknesses
- Hemab Posts Q2 Loss of $24.2M, Gets FDA Nod for Phase 3 Trial
- Hemab Q2: $457.5M Cash, Sutacimig Phase 3 Greenlit, New HMB-003 Program Unveiled
- Hemab Therapeutics Reports Q1 Net Loss of $(22.7)M, EPS $(23.98) Post-IPO
Short Interest & Short Volume
7.54 days to coverFINRA reported short interest of 2,641,038 shares in COAG as of the September 15, 2026 settlement, a 25.3% increase from the prior period — about 7.5 days to cover at its recent average daily volume. On October 2, 2026, 83.0% of COAG volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for COAG, detected from its recent SEC filings · based on capital-structure filings through 2026-05-01.
Initial Public Offering Completed · Substantial Capital Raise
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →